AU2012274156A1 - Method for predicting the clinical response to chemotherapy in a subject with cancer - Google Patents

Method for predicting the clinical response to chemotherapy in a subject with cancer Download PDF

Info

Publication number
AU2012274156A1
AU2012274156A1 AU2012274156A AU2012274156A AU2012274156A1 AU 2012274156 A1 AU2012274156 A1 AU 2012274156A1 AU 2012274156 A AU2012274156 A AU 2012274156A AU 2012274156 A AU2012274156 A AU 2012274156A AU 2012274156 A1 AU2012274156 A1 AU 2012274156A1
Authority
AU
Australia
Prior art keywords
choka
cancer
gene
sample
nsclc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012274156A
Other languages
English (en)
Inventor
Juan Carlos Lacal Sanjuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Traslational Cancer Drugs Pharma SL
Original Assignee
Traslational Cancer Drugs Pharma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Traslational Cancer Drugs Pharma SL filed Critical Traslational Cancer Drugs Pharma SL
Publication of AU2012274156A1 publication Critical patent/AU2012274156A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012274156A 2011-06-20 2012-06-20 Method for predicting the clinical response to chemotherapy in a subject with cancer Abandoned AU2012274156A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11382211.8 2011-06-20
EP11382211 2011-06-20
US201161507833P 2011-07-14 2011-07-14
US61/507,833 2011-07-14
EP11382294.4 2011-09-16
EP11382294 2011-09-16
PCT/EP2012/061790 WO2012175537A1 (en) 2011-06-20 2012-06-20 Method for predicting the clinical response to chemotherapy in a subject with cancer

Publications (1)

Publication Number Publication Date
AU2012274156A1 true AU2012274156A1 (en) 2014-01-23

Family

ID=47422050

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012274156A Abandoned AU2012274156A1 (en) 2011-06-20 2012-06-20 Method for predicting the clinical response to chemotherapy in a subject with cancer

Country Status (11)

Country Link
US (1) US20150004252A1 (enExample)
EP (1) EP2721174A1 (enExample)
JP (1) JP2014527397A (enExample)
KR (1) KR20140047664A (enExample)
CN (1) CN103687964A (enExample)
AU (1) AU2012274156A1 (enExample)
BR (1) BR112013032857A2 (enExample)
CA (1) CA2840129A1 (enExample)
MX (1) MX2013015286A (enExample)
RU (1) RU2014101492A (enExample)
WO (1) WO2012175537A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
US20170305861A1 (en) * 2016-04-25 2017-10-26 Immunomet Therapeutics, Inc Heteroaryl compounds comprising nitrogen and use thereof
ES2899114T3 (es) * 2016-07-25 2022-03-10 Nerviano Medical Sciences Srl Análogos de purina y 3-deazapurina como inhibidores de colina cinasa
US11339447B2 (en) 2017-03-29 2022-05-24 Crown Bioscience, Inc. (Taicang) System and method for determining Kareniticin sensitivity on cancer
CN107050668B (zh) * 2017-06-09 2020-03-31 南京医科大学第一附属医院 基于云处理的放疗效果预测方法
EP3502700A1 (en) * 2017-12-21 2019-06-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods based on the detection of rad51 foci in tumor cells
CN116859058B (zh) * 2023-07-17 2026-08-04 上海中医药大学 一种基于NDR1-Myc互作抗结直肠癌活性分子筛选方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2237332B1 (es) 2004-01-14 2006-11-01 Consejo Sup. Investig. Cientificas Derivados de piridinio y quinolinio.
PL1889920T3 (pl) * 2005-04-13 2010-06-30 Consejo Superior Investigacion Sposób identyfikacji związków do terapii antynowotworowej in vitro
GB0519405D0 (en) * 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
AU2009265121A1 (en) * 2008-07-04 2010-01-07 Traslational Cancer Drugs Pharma, S.L. Methods for the treatment and diagnosis of cancer
EP3133170B1 (en) 2008-09-10 2020-03-18 Rutgers, the State University of New Jersey Imaging individual mrna molecules using multiple singly labeled probes
US20100068302A1 (en) 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
EP2721174A1 (en) 2014-04-23
US20150004252A1 (en) 2015-01-01
JP2014527397A (ja) 2014-10-16
RU2014101492A (ru) 2015-07-27
KR20140047664A (ko) 2014-04-22
WO2012175537A1 (en) 2012-12-27
CN103687964A (zh) 2014-03-26
MX2013015286A (es) 2014-09-25
CA2840129A1 (en) 2012-12-27
BR112013032857A2 (pt) 2017-01-24

Similar Documents

Publication Publication Date Title
JP5926487B2 (ja) ＥｒｂＢ療法に耐性である癌を治療するための方法
CN111373055B (zh) 用于癌症的诊断和治疗方法
RU2706968C2 (ru) Диагностические способы и композиции для лечения глиобластомы
EP2137535B1 (en) Receptor tyrosine kinase profiling
KR100962162B1 (ko) 화학요법에 대한 반응자의 측정
US20150004252A1 (en) Method for predicting the clinical response to chemotherapy in a subject with cancer
US9523691B2 (en) Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis
EP3081941B1 (en) Method for determination of sensitivity to anti-cancer agent
JP2018508183A (ja) 化学療法耐性癌を治療及び診断する組成物及び方法
CN107667119A (zh) 用于癌症的治疗和诊断方法
CN107532217A (zh) 用于癌症的治疗和诊断方法
CN103221825A (zh) 生物标志物和治疗方法
CN107109700A (zh) 用于推导对pd‑1拮抗剂的反应的基因特征生物标志物的系统和方法
JP6675300B2 (ja) 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用
JP2017523776A (ja) 膠芽腫の診断方法及びその治療用組成物
CN102215872A (zh) 用于治疗癌症的方法和组合物
US20200216906A1 (en) Methods and compositions relating to the diagnosis and treatment of cancer
CA3159909A1 (en) Iron-score and in vitro method for identifying mantle cell lymphoma (mcl) subjects and therapeutic uses and methods
CN117881400A (zh) 用于预防或治疗癌症的药物组合物
AU2011223643A1 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2016029090A1 (en) Genospecific radiosensitization
WO2014185528A1 (ja) Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
JP2013510564A (ja) 肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
JP2007522791A (ja) 結腸直腸癌を診断する方法
AU2014348780A1 (en) Biomarker for MELK activity and methods of using same

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application